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S U M M A R Y
Objectives: To determine prognostic factors for mortality in neonates with tetanus and to assess the
associations between prognostic factors and neonatal tetanus (NT) mortality.
Methods: Five databases were searched for studies on prognostic factors and NT mortality published up
to April 2013 to identify studies relevant to this review. Prognostic factors of interest were birth weight,
age at onset of symptoms, age at presentation, delay in presentation, and duration of hospitalization.
Odds ratios (ORs) for prognostic factors and mortality were estimated by random effects models and
stratiﬁed analyses for all studies.
Results: Sixteen studies including a total of 4535 neonates were included in the analysis: nine from
Africa, ﬁve from Asia, and two from Europe. The prognostic factors identiﬁed consistently in the studies
were birth weight, age at onset of symptoms, and age at presentation. Of the 16 studies, only one
assessed all three prognostic factors, ﬁve studies assessed two prognostic factors, and 10 studies
assessed one prognostic factor. Neonates with a low birth weight were more likely to have an increased
odds of NT death (OR 2.09, 95% conﬁdence interval (CI) 1.29–3.37) than normal weight neonates. This
mortality risk was exacerbated for low birth weight neonates with age at onset 6 days (OR 6.80, 95% CI
2.42–19.11). Age at onset 5–7 days was associated with an increased odds of NT death.
Conclusions: Low birth weight predicted an increased odds of death by NT. Age at onset 5–7 days to
diagnosis is crucial in determining survival among neonates with tetanus.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Neonatal tetanus (NT), caused by Clostridium tetani, is a
frequently fatal infection of the neonatal period. Infection occurs
when the umbilical cord becomes contaminated as a result of
unclean childbirth or cord-care practices. If contamination occurs
when the cord is cut or shortly after birth, symptoms begin within
3–12 days.1
NT is an underreported disease2 and remains a major but
preventable cause of newborn and infant deaths in many
developing countries.3 Considerable progress has been made since
1989 when the World Health Assembly called for the elimination
of NT by 1995, with a reduction in the number of endemic
countries from 106 to 30 as of May 2013.4 The majority of the
endemic countries are in Africa and a minority in Asia and
Oceania.4 The global burden of NT reduced from over 600 000 in
1990 to fewer than 60 000 in 2008.5 NT has a high case fatality rate
(CFR), and even with treatment, 10–90% of neonates with NT die,
depending on the intensity of supportive care;6 others survive with* Corresponding author. Fax: +1 403 270 7307.
E-mail address: jgalambo@ucalgary.ca (J.A. Lambo).
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http://dx.doi.org/10.1016/j.ijid.2013.05.016brain damage.7–9 Immunization of pregnant women and all
women of childbearing age with tetanus toxoid vaccine in high-
risk countries is the World Health Organization (WHO) recom-
mended strategy for prevention.10
The risk factors for the development of NT are well documented
and relate to the cultural diversity of hygienic childbirth practices
and cord care,11,12 lack of skilled birth attendants, parent’s
illiteracy,11 lack of antenatal care including a low level of
immunization against tetanus,11 seasonality,12 geographical loca-
tion or climate,12 prevalence of spores of C. tetani,13 and rural
agricultural settled populations.12 On the other hand, the
association between prognostic factors and mortality in NT are
not well understood. Previous studies have shown that a short
incubation period and low birth weight14,15 are associated with a
high mortality rate and are poor prognostic factors.
One Cochrane meta-analysis has compared diazepam alone,
phenobarbitone and chlorpromazine, or phenobarbitone and
chlorpromazine and diazepam for the treatment of NT. Another
systematic review has estimated the effect on NT mortality of the
immunization of pregnant women or women of childbearing age
with tetanus toxoid (TT). In the ﬁrst study, a statistically signiﬁcant
difference in the treatment group with diazepam alone was found
in the number of deaths and other outcomes, such as severity ofses. Published by Elsevier Ltd. All rights reserved.
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immunization of pregnant women or women of childbearing age
with at least two doses of TT was estimated to reduce mortality
from NT by 94%.17
Previous observational studies of NT have compared NT
survivors with those who died and reported a signiﬁcant effect
on mortality of three prognostic factors: age at onset of symptoms
(incubation period), birth weight, and age at presentation.
However, to date, no quantitative synthesis of research results
has been published.
The aims of the present study were two-fold. Using observa-
tional data from different countries we sought to: (1) systemati-
cally review the literature on NT to determine the prognostic
factors for mortality in neonates with tetanus, and (2) assess the
associations between prognostic factors and the risk of NT
mortality using a meta-analytic methodology.
2. Methods
This study was performed using a predetermined protocol and
in accordance with the Meta-analysis Of Observational Studies in
Epidemiology (MOOSE) statements.18
2.1. Search strategy and study selection
We searched PubMed, MEDLINE, EMBASE, CINAHL, and Global
Health to April 2013 to identify studies relevant to this review.
Database searches combined terms from three themes: (1) infants
or neonates; (2) tetanus; (3) mortality or prognosis or risk. Terms
were searched as both keywords (title/abstract words) and subject
headings, as appropriate. We also searched the references of
included papers to identify additional articles of relevance, and
reviewed all abstracts from conference proceedings from 2008 to
2012 in the following infectious diseases meeting proceedings:
International Congress on Infectious Diseases, International
Meeting on Emerging Diseases and Surveillance, and the Interna-
tional Society for Infectious Diseases – Neglected Tropical Diseases.
A thorough description of the search strategy is available upon
request from the authors of this study.
Abstracts of all relevant papers identiﬁed by the search strategy
were selected for full text retrieval. The authors independently
used the eligibility criteria check list to apply the inclusion criteria
identiﬁed below to the papers. Duplicates were identiﬁed by
importing all searched references into the Reference Manager 12
Program. Disagreements regarding inclusion of papers were
resolved through discussion and consensus.
2.2. Inclusion and exclusion criteria
To be included in the systematic review and meta-analysis of
this study, all articles had to meet the following criteria: (1) used
any of the following study designs: retrospective or prospective
cohort studies on NT; (2) population of focus was neonates (0–28
days old) with NT treated within a hospital setting; (3) study
reported on one of the prognostic factors identiﬁed or a
combination thereof: age at onset of symptoms, age at presenta-
tion, low birth weight, delay in presentation, and duration of
hospitalization; (4) study used NT survivors treated in hospitals as
a comparison; (5) main outcomes measured included mortality in
hospital; and (6) all neonates in the study received the standard
protocol for NT care and treatment (i.e., anti-tetanus serum,
antibiotics, anticonvulsants, and sedatives; and all neonates were
fed with expressed breast milk). Articles were excluded if they
were published prior to the year 1974, i.e., before the case
deﬁnition for NT was ﬁrst established by the WHO.19For the purposes of this study, assuming infection occurred at
birth, the age at onset of symptoms was regarded as the incubation
period and was deﬁned as the period of time in days from birth to
the ﬁrst symptoms of NT.20 Age at presentation was deﬁned as the
period of time in days from birth to presentation to the hospital.20
The low birth weight prognostic factor was deﬁned as any weight
below 2.5 kg (or its equivalent in other units) – this is in accordance
with WHO guidelines.21
2.3. Outcome measures
The primary outcome measure was mortality in hospital
regardless of time. We used CFRs based on the selected prognostic
factors (birth weight, age at onset, and age at presentation) as a
measure of mortality. The CFR is a clinical measure of severity of
disease and was calculated from the reported number of NT deaths
divided by the total NT cases per study.22
2.4. Data extraction and quality assessment
The following data were extracted: sample size, location of
study, study design, sex, number of NT cases, number of NT deaths,
number of NT survivors, birth weight mean and standard deviation
(SD), age at presentation mean and SD, age at onset mean and (SD),
number of patients discharged against medical advice (DAMA) and
lost to follow-up, and CFRs. Any discrepancies in data collection
during the data extraction stage were resolved by consensus.
The authors independently assessed the methodological quality
of the selected studies according to the recommendations of well-
documented quality appraisal guidelines.23,24 Quality items were
selected after a review of the NT literature and on the basis of
relevance to the objectives of the review. Each study was assessed
to determine if it satisﬁed the following quality items that were
operationalized: (1) the diagnostic criteria for NT were based on
clinical signs and symptoms or the WHO case deﬁnition;25 (2) the
study sample was described (including clinical and demographic
characteristics) as representative of the community studied; (3) all
neonates were admitted following diagnosis; (4) the prognostic
factors were deﬁned; (5) outcome was known for all or a high
proportion of the patients; (6) outcome was appropriately
measured as the CFR; (7) the results had been adjusted for at
least two confounding variables/covariates.
Each quality item was assessed with a ‘yes’ if the study provided
available data on the item and/or clearly and adequately described
key characteristics of the item, and otherwise with a ‘no’. Items
were classiﬁed as ‘not reported’ when the study did not provide
available data. The item responses were then used to inform and
assess potential biases.21 Disagreements in any of the quality
measures for a speciﬁc study were resolved by consensus.
2.5. Measuring inter-rater agreement
The Cohen’s (unweighted) kappa coefﬁcient (k) was used to
measure agreement between the two reviewers. The k for abstract
screening was 0.937 with a 95% conﬁdence interval (CI) of 0.919–
0.954.
2.6. Data synthesis and analysis
Initially we collected data on ﬁve prognostic factors identiﬁed
from the retrieved literature on NT. However, because prognostic
factors such as length of stay in hospital and delay in presentation
to hospital are derived variables from disease onset and outcome,
most studies did not report consistently on them. Therefore, we
focused our review on three prognostic factors – age at onset of
symptoms, birth weight, and age at presentation – because a
Table 1
Characteristics of studies included in the systematic review of prognostic factors for mortality in neonatal tetanus, 1974–2011
Study Country Number of
patients
DAMA/
outcome
unknown
Male
deaths, %
Female
deaths, %
Male
cases, %
Female
cases, %
Birth weight
(kg), mean (SD)
Age at onset
of symptoms
(days), mean (SD)
Age at
presentation
(days), mean (SD)
Outcomes
reported
Number of
deaths
Adjusted
case fatality
rate,d %
Nigam et al. (1974)27,a,b India 72 0 63.0 37 72.2 27.8 NR NR NR 63 87.5
Mazumder and Chakraborty (1974)28,b India 519 0 NR NR 66.7 33.3 NR NR NR 494 95.2
Blankson (1977)29,a Ghana 249 0 59.1 40.9 53 47 NR NR NR 159 63.9
Okoro and Okeahialam (1987)30,c Nigeria 189 0 56e 44e 58.2 41.8 NR NR NR 98 51.9
Kumar et al. (1988)31,b India 385 0 86.9 13.1 87 13 NR NR NR 320 83.1
Einterz and Bates (1991)15,b Nigeria 237 0 NR NR 56.1 43.9 NR 6.5 (3.37) NR 149 62.9
Gurses and Aydin (1993)32,a,b Turkey 133 0 57.4 42.6 59.4 40.6 NR NR NR 54 40.6
Davies-Adetugbo et al. (1998)14,b,c Nigeria 174 7 57.3 42.7 58.6 41.4 2.68 (0.44) NR 7.2 (2.7) 96 57.5
Kurtoglu et al. (1998)33,c Turkey 207 0 75.3 24.7 77.8 22.2 NR 6 7.6 97 46.9
Patel and Mehta (1999)34,b India 1490 0 64.4 35.6 64.1 35.9 NR NR NR 1287 86.4
Nida (2001)35,b Ethiopia 43 1 NR NR 65.1 34.9 NR NR 9.5 29 69.0
Ejike et al. (2003)36,a Nigeria 30 0 NR NR 60.0 40 NR NR 6.3 12 40
Amsalu and Lulseged (2005)37,a,b Ethiopia 62 2 NR NR 71 29 NR NR NR 46 76.7
Ogunlesi et al. (2007)38,a,c Nigeria 162 8 NR NR 54.9 45.1 2.7 (0.5) NR 7.6 (2.9) 71 46.1
Fetuga et al. (2010)39,a Nigeria 175 24 61.5 38.5 62.3 37.7 2.7 (0.5) NR 8.6 (4.5) 96 63.6
Lambo et al. (2011)40,a,b,c Pakistan 408 132f 76.4 23.6 74 26 2.6 (0.5) 6.3 (2.7) 8.2 (3.5) 123 44.6
DAMA, discharged against medical advice; SD, standard deviation; NR, not reported.
a Of the eight studies including data that were used to estimate the odds ratio for the age at presentation meta-analysis, only four reported the mean age at presentation. In addition Davies-Adetugbo et al. (1998), Kurtoglu et al.
(1998), and Nida (2001) also reported the mean age at presentation but did not report an odds ratio for age at presentation.
b Of the 10 studies including data thatwere used to estimate the odds ratio for the age at onsetmeta-analysis, only two reported themean age at onset. In addition Kurtoglu et al. (2008) provided themean age at onset but no data on
the age at onset odds ratio.
c Of the ﬁve studies including data that were used to estimate the odds ratio for the birthweightmeta-analysis, only three reported themean birthweight. In addition Fetuga et al. (2010) provided themean birthweight but no data
on a birth weight odds ratio.
d The number of cases for DAMA/unknown were subtracted from the at-risk population (denominator) to give the adjusted case fatality.
e Data were only available for the retrospective cohort of Okoro and Okeahialam (1987); data were not available for the prospective cohort.
f Seventy-nine cases for which outcome was unknown and 53 cases discharged against medical advice (DAMA).
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J.A. Lambo, E.A. Anokye / International Journal of Infectious Diseases 17 (2013) e1100–e1110 e1103number of studies have been published examining the association
between these ‘core prognostic factors’ and mortality outcomes in
NT.
We performed an analysis according to the data reported by the
original authors, using the odds ratio (OR) for dichotomous data, the
CFR, and 95% CIs. We applied both random and ﬁxed effects models
to estimate the pooled ORs and their respective 95% CIs.26We found
that the results were virtually identical, except that the random
effects model gave greater weights to small studies. We used
random effects modeling in all analyses because most of the studies
included more participants and the pooled result for the primary
outcome showed little heterogeneity except for the ‘age at onset’.
Stratiﬁed analyses for all studies were performed using the Mantel–
Haenszel OR to adjust the prognostic factors and look for effect
modiﬁcation and confounding. We assessed the heterogeneity of
different studies by using the I2 statistic; I2> 50% is equivalent to
substantial heterogeneity. We assessed publication bias from the
funnel plots of standard error (SE) against the log OR using Begg and
Egger’s test of the intercept to determine statistical signiﬁcance.
To assess the sources of heterogeneity, we conducted a subgroup
meta-analysis. We examined the effects of prognostic factors
according to study size and outcome measure (i.e., number of NT
deaths) by exploring for differences in sample size between large
and small studies (number of NT cases <50 vs. 51–100 vs. >100), and
mortality (number of deaths from NT <50 vs. 51–100 vs. >100).
We conducted a meta-analysis for the primary outcome of
interest – in-hospital death – using birth weight, age at onset of
symptoms, and age at presentation as exposure variables. We
stratiﬁed the prognostic factors according to the data provided by
the original authors using different cut-offs of younger age and low
birth weight as the exposure of reference or the ‘exposed’ group, as
follows: birth weight <2.5 kg (exposure of reference) vs. 2.5 kg;
age at onset of symptoms 5 to 7 days (exposure of reference) vs.
>7 days; and age at presentation 6 to 10 days (exposure of
reference) vs. >10 days. For each study, the stratum-speciﬁc OR
estimate of NT mortality for the prognostic factor was calculated
using the adjusted and/or unadjusted OR obtained in that study
and the CFR for the prognostic factor. In meta-analyses, studies
using different cut-offs of age were grouped together to determine
a pooled OR estimate for the prognostic factor.
All statistical analyses were completed using STATA 11.0
(StataCorp. LP, College Station, TX, USA).
3. Results
Abstract screening yielded 1314 citations that potentially met
our inclusion criteria, and after removing 339 duplicates, 975
abstracts were left for screening. An additional 667 abstracts were
removed at the abstract level for not being focused on NT or being
reviews, leaving a potential 311 articles for full text review. During
full text review, 295 abstracts were excluded because they did not
satisfy all the selection criteria or they did not assess outcomes of
interest. The remaining 16 studies were included in our meta-
analysis (Figure 1). Table 1 presents a description of the
participants, the prognostic factors, and the outcomes of NT.
The 16 studies14,15,27–40 that met our inclusion criteria
comprised a total of 4535 neonates with NT. Based on the reported
3194 deaths and after adjusting for neonates discharged against
medical advice and for whom the outcome was unknown (i.e., 174
cases), this was equivalent to a case-fatality of 73.2% for all studies
(95% CI 71.9–74.5%; range 40.0–95.2%). The studies originated
from several regions: ﬁve from Asia, nine from Africa, and two from
Europe. The male:female sex ratio of cases ranged from a low of
1.1:1 to a high of 6.7:1.
A variation in the quality of the studies was found (Table 2). Of
the 16 studies included, 15 had a retrospective cohort design and
J.A. Lambo, E.A. Anokye / International Journal of Infectious Diseases 17 (2013) e1100–e1110e1104one had an ambidirectional cohort design.30 Fourteen of the 16
studies (87.5%) used the clinical criteria (i.e., based on signs and
symptoms of NT) to diagnose NT, and only two studies (12.5%) used
the WHO standard case deﬁnition25. Only one of the 16 studies
provided information on all three prognostic factors, ﬁve studies
on two prognostic factors, and 10 studies on one prognostic factor.
All 16 studies assessed case fatality as a measure of mortality. In
addition, sample size and number of deaths from NT varied. Six
studies reported on the delay in presentation and ﬁve on the
duration of hospitalization as prognostic factors for mortality;
none provided data for us to estimate ORs for these prognostic
factors. Finally, other potential confounding factors such as sex,
gestational age, comorbidities, and interactions between prognos-
tic factors and risk of mortality were not addressed in over 80% of
the studies.
Overall, most studies found a moderately signiﬁcant association
between mortality and age at onset, and between mortality andFigure 1. Flow chart of the literatuage at presentation. Only eight of the 10 studies on age at onset,
and six of the eight on age at presentation, found a statistically
signiﬁcant relationship with mortality. However, the direction of
the association was always the same: the younger the age at onset
or at presentation, the greater the mortality and severity of disease
(Table 3).
3.1. Low birth weight meta-analysis
The meta-analysis of the relationship between birth weight and
mortality included effect size estimates from ﬁve studies. The
meta-analysis showed a moderate statistically signiﬁcant differ-
ence in the odds of death (OR 1.81, 95% CI 1.17–2.78; n = 814), with
modest heterogeneity (I2 = 6.1%; p = 0.372) (Figure 2) across the
studies. The odds of mortality were 1.8 times higher for low birth
weight babies compared to normal weight babies. The funnel plot
did not show a statistically signiﬁcant relationship between the SEre search process and results.
Table 3
Findings from studies included in the systematic review of prognostic factors for mortality in neonatal tetanus, 1974–2011
Study Study design Main ﬁndings Notes
Nigam et al. (1974)27 Retrospective cohort Mortality, age at onset 5 days:
unadjusted OR 0.4, 95% CI 0.03–23.5;
mortality, age at presentation 8 days:
unadjusted OR 2.3, 95% CI 0.4–15.4
69% of deaths occurred with the age at onset
6–10 days
Mazumder and
Chakraborty (1974)28
Retrospective cohort Mortality, age at onset 7 days:
unadjusted OR 3.6, 95% CI 1.3–12.7
61% of neonates died with the age at onset 7 days and
percentage of death declined to 21% at 3 weeks
Blankson (1977)29 Retrospective cohort Mortality, age at presentation 7 days:
unadjusted OR 3.9, 95% CI 2.1–7.2
80% of deaths occurred by the day 7 of admission and
declined with increase in age at presentation.
A comparison of male:female ratio on admission
to male:female ratio among neonates who died
showed that there were more survivors among
female neonates
Okoro and
Okeahialam (1987)30
Ambidirectional cohorta Mortality, low birth weight:
unadjusted OR 2.9, 95% CI 0.9–10.9
A reduction in case fatality from 63% in retrospective
study to 34% was achieved in prospective study due to
improved nursing care
Kumar et al. (1988)31 Retrospective cohort Mortality, age at onset 7 days:
unadjusted OR 1.1, 95% CI 0.6–2.0
Age at onset was 7 days in 70% of neonates who died
and in 68% of survivors
Einterz and Bates (1991)15 Retrospective cohort Mortality, age at onset 6 days:
unadjusted OR 13.1, 95% CI 6.5–26.4
Mortality in neonates with age at onset 6 days or less
was 86% compared with 25% with onsets greater than 6 days
Gurses and Aydin (1993)32 Retrospective cohort Mortality, age at onset 5 days:
unadjusted OR 15, 95% CI 4.5–63;
mortality, age at presentation >10 days:
unadjusted OR 4.1, 95% CI 1.4–13.2
Age at onset was 5 days in 44% of neonates who died
and in 5% of survivors. In contrast, age at presentation
was 10 days in 89% of neonates who died and in 66% of
survivors
Davies-Adetugbo
et al. (1998)14
Retrospective cohort Mortality, age at onset 6 days:
adjusted OR 3.1, 95% CI 1.4–6.5;
mortality, low birth weight:
adjusted OR 2.4, 95% CI 1–5.8
Mortality in neonates with low birth weight was 74%
compared with 48% with birth weights 2.5 kg
Kurtoglu et al. (1998)33 Retrospective cohort Mortality, low birth weight:
unadjusted OR 2.3, 95% CI 0.4–14.8
Mortality in neonates with low birth weight was
67% compared with 46% with birth weights 2.5 kg
Patel and Mehta (1999)34 Retrospective cohort Mortality, age at onset <7 days:
unadjusted OR 11.3, 95% CI 8–15.9
Mortality in neonates with age at onset 7 days or less
was 94% compared with 59% with onsets greater
than 7 days
Nida (2001)35 Retrospective cohort Mortality, age at onset 7 days:
unadjusted OR 8.4, 95% CI 0.9–391.6
Mortality in neonates with age at onset 7 days or less
was 92% compared with 59% with onsets greater than
7 days
Ejike et al. (2003)36 Retrospective cohort Mortality, age at presentation 6 days:
unadjusted OR 1.7, 95% CI 0.3–9.9
Age at presentation was 6 days in 58% of neonates
who died and in 44% of survivors
Amsalu and Lulseged (2005)37 Retrospective cohort Mortality, age at onset <7 days:
unadjusted OR 5.1, 95% CI 1.2–22.8;
mortality, age at presentation 10 days:
unadjusted OR 5.8, 95% CI 0.9–33.5
Age at onset was 7 days in 74% of neonates who died
and in 33% of survivors. In contrast, age at presentation,
was 10 days in 91% of neonates who died and in 64%
of survivors
Ogunlesi et al. (2007)38 Retrospective cohort Mortality, age at presentation 7 days:
unadjusted OR 2.7, 95% CI 1.3–5.5;
mortality, low birth weight:
unadjusted OR 1, 95% CI 0.4–2.1
Age at presentation, was 7 days in 72% of neonates
who died and in 48% of survivors. Mortality in neonates
with low birth weight was 44% compared with 44% with
birth weights 2.5 kg
Fetuga et al. (2010)39 Retrospective cohort Mortality, age at presentation 7 days:
adjusted OR 1.82, 95% CI 0.9–2.73
Age at presentation, was 7 days in 58% of neonates
who died and in 31% of survivors
Lambo et al. (2011)40 Retrospective cohort Mortality, age at onset 6 days:
adjusted OR 2.1, 95% CI 1.1–3.9;
mortality, low birth weight:
adjusted OR 1.6, 95% CI 0.8–3.3;
mortality, age at presentation 8 days:
adjusted OR 2.6, 95% CI 1.5–4.5
Age at onset was 6 days in 80% of neonates who died and
in 64% of survivors. In contrast, age at presentation was
8 days in 82% of neonates who died and in 63%
of survivors
OR, odds ratio; CI, conﬁdence interval.
a Study includes both retrospective and prospective cohort designs.
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The CFR was 46.2% (Table 4).
3.2. Age at presentation meta-analysis
The meta-analysis of the relationship between age at presenta-
tion and mortality is comprised of effect size estimates from eight
studies, with a combined study population of 1189 neonates. The
meta-analysis of the results of 6–10 days and >10 days
comparisons showed a signiﬁcant relationship between age at
presentation and mortality (OR 3.13, 95% CI 2.32–4.221; I2 = 0%;
p = 0.936) (Figure 3). The odds of mortality for neonates of age at
presentation 6–10 days are 3.13 times the odds of mortality for
neonates of age at presentation >10 days.
In the stratiﬁed analyses (sub-analyses) using different cut-offs
for the age at presentation (6–8 days vs. >10 days, and 10 daysvs. >10 days), the pooled result showed a statistically signiﬁcant
odds of death from NT in both age strata 6–8 days (OR 3.00, 95% CI
2.18–4.11; n = 996; I2 = 0%; p = 0.906) and 10 days (OR 4.56, 95%
CI 1.80–11.55; n = 100; I2 = 0%; p = 0.748). However, it was not
possible to distinguish between the effect size estimates due to the
overlapping age strata and CIs. The funnel plot showed a
statistically signiﬁcant relationship between the SE and the log
OR using both tests of signiﬁcance, indicating bias against small
studies reporting non-signiﬁcant results (graph not shown). The
case fatality was 52.6%.
3.3. Age at onset of symptoms meta-analysis
The meta-analysis of the relationship between age at onset of
symptoms and mortality is comprised of effect size estimates from
10 studies, with a combined study population of 3350 neonates. In
Figure 2. Forest plot of the meta-analysis of the association between birth weight and neonatal tetanus mortality.
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meta-analysis showed a marginally statistically signiﬁcant differ-
ence in the odds of death (OR 4.43, 95% CI 2.14–8.16), with
substantial heterogeneity across the studies (I2 = 86.1%; p < 0.001)
(Figure 4). However, the pooled ORs from studies comparing
different cut-offs for the age at onset: 5–6 days vs. >5–6 days (OR
4.70, 95% CI 1.78–12.38; n = 854) with age at onset 7 days vs. >7
days (OR 4.26, 95% CI 1.20–15.13; n = 2496) showed no statistically
signiﬁcant difference between the results in view of the wide,
overlapping CIs and substantial heterogeneity (Figure 4). A funnel
plot of the SE log OR vs. the log OR showed asymmetry, suggestingTable 4
Crude and stratiﬁed analysis of prognostic factors for mortality in neonatal tetanus stu
Prognostic factor Category of exposed
and unexposed
(reference) groups
Died Survived OR for 
(95% CI
Birth weight, kg 2.5 kg vs. 94 76 1.58 (1
2.5 kg (reference) 282 362
Age at presentation, days 6 to 8 vs. 374 246 2.27 (1
>8 (reference) 148 221
10 vs. 90 61 4.72 (2
>10 (reference) 10 32
All 6 to 10 vs. 464 307 2.42 (1
Combined (reference) 158 253
MHb estimate OR,
adjusted for age
at presentation
2.46
Age at onset, days 5 to 6 vs. 282 153 2.62 (1
>6 (reference) 173 246
7 vs. 1603 123 4.48 (3
>10 (reference) 573 197
All 5 to 7 vs. 1885 276 4.05 (3
Combined (reference) 746 443
MHb estimate OR,
adjusted for age
at onset
3.50
OR, odds ratio; CI, conﬁdence interval; CFR, case fatality ratio.
a All odds ratios and their conﬁdence intervals shown in this table are crude and have n
b MH, Mantel–Haenszel.42the evidence of publication bias, particularly the absence of small
negative studies (p for bias < 0.001, Begg’s test; or p < 0.001,
Egger’s test) (Figure 5).
A sensitivity analysis done by restricting the meta-analysis to
studies that had a sample size >50 (OR 4.30, 95% CI 2.03–9.11) and
studies having >50 NT deaths (OR 4.22, 95% CI 1.80–9.45) showed
that the overall pooled OR is fairly stable regardless of the study
quality and sample size, enhancing the robustness of our ﬁndings.
The CFR was 78.5%.
Table 4 shows the results of stratiﬁcation of prognostic factors
by age groups. The proportions of neonates exposed to all of thedies
mortalitya
)
Proportion exposed
among deceased
neonates, % (95% CI)
Proportion exposed
among survivors,%
(95% CI)
CFR, % (95% CI)
.11–2.26) 25.00 (20.70–29.70) 17.35 (13.92–21.23) 46.2 (42.7–49.6)
.73–2.97) 71.65 (67.57–75.48) 52.68 (48.04–57.28) 52.8 (49.6–55.9)
.06–11.50) 90.00 (82.38–95.10) 65.59 (55.02–75.14) 51.8 (44.5–59.0)
.87–3.11) 74.60 (70.98–77.98) 45.18 (41.00–49.41) 52.6 (49.7–55.5)
.96–3.49) 61.97 (57.3–66.4) 38.34 (33.5–43.3) 53.3 (49.8–56.6)
.48–5.77) 73.66 (71.7–75.5) 38.92 (33.5–44.5) 87.2 (85.8–88.4)
.40–4.83) 71.64 (69.8–73.3) 38.40 (34.8–42.0) 78.5 (77.1–79.9)
ot been assigned random effects weights as seen in their corresponding forest plots.
Figure 3. Forest plot of the meta-analysis of the association between age at presentation and neonatal tetanus mortality.
Figure 4. Forest plot of the meta-analysis of the association between age at onset of symptoms and neonatal tetanus mortality.
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Figure 5. Publication bias meta funnel plot for age at onset dataset.
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deceased neonates compared to survivors. There was variation
in the odds of mortality as shown by the different ORs in the age
groups. The Mantel–Haenszel (MH) OR for age at presentation
(2.46) was not meaningfully different from the unadjusted OR
(2.4). The MH OR for age at onset (3.5) was lower than the
unadjusted OR (4.1). Stratiﬁed analyses thus demonstrated effect
modiﬁcation (age at onset and age at presentation) and
confounding (age at onset).
3.4. Interactions between prognostic factors, confounding, and NT
mortality
Three studies used multivariable models for risk of mortality
and adjusted for potential confounders such as male sex, maternal
TT immunization, and comorbidities. None of the studies adjusted
for gestational age. When the meta-analysis was restricted to the
three studies that examined birth weight, the relationship between
low birth weight and risk of mortality remained statistically
signiﬁcant (OR 2.09, 95% CI 1.29–3.37), with little heterogeneity
(I2 = 0%; p = 0.667). Meta-analysis of two studies showed that the
relationship between age at presentation (7–8 days) and risk ofFigure 6. Forest plot of studies including an interactiomortality remained statistically signiﬁcant (OR 3.70, 95% CI 1.62–
8.43), with moderate heterogeneity (I2 = 58.9%; p = 0.115). Meta-
analysis of the two studies that examined age at onset (6 days)
also showed that the relationship between the age at onset and risk
of mortality remained statistically signiﬁcant (OR 2.49, 95% CI
1.55–3.98), with little heterogeneity (I2 = 0%; p = 0.453).
Finally, when the meta-analysis was restricted to two studies
that examined the association between age at onset (6 days) and
low birth weight together, the product term was statistically
associated with the risk of mortality (OR 6.80, 95% CI 2.42–19.11;
I2 = 0%; p = 0.320), reﬂecting the fact that the effect of age at onset
varied by the baseline birth weight (Figure 6).
4. Discussion
Tetanus in the neonatal period is a severe disease, yet little is
known about the prognostic factors for mortality. In this
systematic review and meta-analysis, we determined the prog-
nostic factors and their association with NT mortality. Based on
studies that used a retrospective cohort design, we identiﬁed 16
studies relating to three prognostic factors and mortality.
This study suggests that low birth weight neonates are at
increased odds of death from NT and that the mortality risk is
exacerbated for low birth weight neonates with age at onset 6
days. The study demonstrated statistically signiﬁcant higher odds
of mortality for age at onset compared to age at presentation and
birth weight. Stratiﬁcation of the results by age groups showed
both confounding and effect modiﬁcation. The increased odds of
mortality for age at onset may be attributable to the large sample
size in these studies. Given that the age at onset is a crucial
prognostic factor, it may have been more accurately documented
and reported in the case histories of neonates than the other
prognostic factors.
The reason for the inverse association between mortality and
the age at onset and age at presentation, when the likelihood of
survival is expected to increase, is not clear. A possible explanation
may be that because maximum mortality was seen in neonates
with age at onset 5–7 days and age at presentation of 6–10 days,
the association between mortality and age at onset and between
mortality and age at presentation may have been masked byn of birth weight <2.5 kg and age at onset 6 days.
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may account for the overlapping CIs observed in the stratiﬁed
analyses, and the latter may be a reﬂection of the fact that the peak
incidence occurs on the sixth day of life but neonates were brought
to the hospital in smaller numbers up to 29 or 30 days of age.28,41
Inaccurate histories may have led to misclassiﬁcation of cases in
the age strata and confounded the results. The overall crude OR of
4.1 for mortality and age at onset was partially due to confounding
by age,42 as shown by the adjusted OR being only 3.5. However,
these results should be interpreted with caution and within the
context of overlapping age strata and inadequate sample size.
It is difﬁcult to ascertain whether the differences in mortality
related to the prognostic factors are real or the result of selection
bias in the studies. There is a great variation in the quality of data
reported in these studies as evidenced by the lack of completeness
and accuracy of the data. We could not identify the problem with
data collection and completeness of reporting in these studies as
these may be local and surveillance-related factors. These results
may reﬂect underreporting of NT as surveillance systems do not
capture those NT deaths that occur at home and those for whom
medical care at a hospital was not sought, with birth and death not
being reported.10
The overall CFR for NT for the study period was 73% based on 16
studies reporting on 4535 neonates. These ﬁndings emerged after
combining the results of studies that had similar designs, came
from a wide range of settings, and included neonates. The age at
onset of symptoms was associated with the most severe disease
with a CFR of 79%; the CFR associated with age at presentation
(53%) was greater than that of birth weight (46%). It appears that
the degree of severity of disease may be a reﬂection of the
underlying effect of the prognostic factors on mortality.
The variation in mortality by prognostic factors suggests that
the period 5–7 days (for age at onset of symptoms) from disease
onset to diagnosis, or 6–10 days (for age at presentation) from
disease onset to admission to hospital, is associated with the
greatest burden of disease in terms of severity and death. The study
showed a statistically signiﬁcant odds of mortality for age at onset
around the 5–7 days of disease onset. This ﬁnding may be used to
develop modeling of NT mortality using birth weight and age at
onset as predictive tools for the severity of disease. This would help
clinicians to identify a cohort of fatal cases, which would be
neonates in most urgent need of attention and treatment. The
effects of prognostic factors on longer-term outcomes have not
been fully explored. With regard to policy implications, focused
long-term follow-up studies are needed to investigate the effects of
prognostic factors in early childhood after NT.
In this meta-analysis, the signiﬁcant heterogeneity among the
10 studies reporting on the age at onset of symptoms and
mortality, was not explained by the study size and the number of
NT deaths. However, the heterogeneity was limited to large studies
(with sample size >100 and number of deaths >50) for which the
age at onset of symptoms was reported to be between 6 and 7 days.
A potential source of this heterogeneity may be related to the
variations in conditions and reporting of age at onset of symptoms,
since this a crucial prognostic factor, making it difﬁcult to compare
results from one study to another.15
Our study is beset with several limitations. First and most
importantly the number of studies included. Overall we included
16 studies and our estimates relied on unadjusted ORs and
estimates of CFR that in most studies did not report on loss to
follow-up, cases for which outcomes were unknown, and neonates
discharged against medical advice. Second, the reporting of
prognostic factors was not complete across studies. In fact, only
one of the 16 articles provided data on all prognostic factors.
Whereas there are more studies that reported on age at onset (10/
16) than age at presentation (8/16), only ﬁve out of 16 reported onbirth weight. None of the studies provided data on duration of
hospitalization and delay in presentation, hence we were not able
to assess their relationships to mortality. Third, there was a great
variation in study quality, as ﬁndings were based on incomplete
data reporting and inaccurate histories of prognostic factors.
Fourth, given the selective reporting of potential confounders in
the primary studies, we cannot completely exclude the possibility
that non-surviving neonates enrolled in the studies analyzed died
of causes other than tetanus. Epidemiological data on a possible
effect of changes to cord care and TT vaccination uptake on the
odds of mortality over the 37-year time frame cannot be
extrapolated. Fifth, another limitation is the exclusion of studies
published before 1974 – the inception year of the Expanded
Program on Immunization (EPI) by the WHO – on the basis that NT
was not a reportable disease before 1974.19 This was related to
constraints such as varying quality of reporting of NT cases from
non-neonatal cases, lack of standard case deﬁnition and surveil-
lance for NT before 1974, and assignment of severity scores to
prognostic indicators, which are factors that may lead to potential
misclassiﬁcation of cases and biased estimates. Furthermore, there
is a potential risk of bias related to severity of disease, as only the
most severe cases, most leading to death, might have been
detected in these hospital-based studies, excluding cases that did
not have access to health care facilities. Finally, NT usually occurs
in resource-poor and rural settings where there is limited access to
health facilities and most deaths occur at home, with birth and
death not being reported (Vandelaer et al.10).
In conclusion, evidence suggests that age at onset 5–7 days is
associated with an increased odds of death and that low birth
weight neonates are at increased odds of death from NT in
comparison to normal weight neonates. We also identiﬁed that the
short window from onset of NT to diagnosis or presentation to the
hospital is crucial in determining survival among neonates. The
impacts of other prognostic factors on long-term outcomes related
to NT have not yet been explored; comorbidities, gestational age,
and other potential confounders will require further study. There
remains a need for focused long-term follow-up studies to
investigate the effects of prognostic factors in early childhood
after NT. It is imperative to strengthen and support surveillance
systems for NT reporting.
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